Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Efavirenz 400 mg with Rifampicin and Isoniazid
NCT02832778Phase 1Unknown
- Sponsor
- St Stephen's AIDS Trust
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of efavirenz in human immunodeficiency virus infection (HIV) (2 arms), sponsored by St Stephen's AIDS Trust. Primary endpoint: Steady-state plasma concentrations of efavirenz at Day 28. Status: unknown.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02832778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02832778.